GEN Exclusives

More »

GEN News Highlights

More »
Aug 28, 2007

Ipsogen Accesses Affymetrix Microchip Technology for Development of IVD Tests

  • Affymetrix and Ipsogen signed a Powered by Affymetrix™ (PbA) agreement. With this transaction, Ipsogen gains nonexclusive access to Affymetrix microarray technology to develop and market in-vitro diagnostic (IVD) tests, initially for breast cancer, on a worldwide basis.

    The PbA agreement enables Ipsogen to incorporate Affymetrix arrays into its diagnostic products. The resulting microarray-based tests will, the companies report, enable clinicians to provide more efficient and complete methods to diagnose, classify, and manage patients suffering from cancer.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using CRISPRs to Tame GMOs

With more climate-induced droughts and insect infestations on the horizon do you think technologies like CRISPR will change a lot of people’s minds about GMOs, including genetically engineered foods?

More »